Revolution Medicines’ RAS-targeting daraxonrasib moved closer to a pivotal oncology milestone after Phase 3 results in metastatic pancreatic ductal adenocarcinoma. The company reported that daraxonrasib improved survival versus standard chemotherapy in a trial designed around RAS variant subgroups. Follow-on financing and earlier market chatter have underscored investor appetite for differentiated targeted approaches in pancreatic cancer, where unmet need remains high and chemotherapy options are limited. The daraxonrasib readouts add to growing evidence that event-driven RAS inhibition may deliver clinically meaningful outcomes in selected molecularly defined patients. The program’s forward path will depend on confirmatory analysis and regulatory strategy as the company positions daraxonrasib within the broader RAS inhibitor landscape.